✦ AI AI Company Comparison

Canva vs Eikon Therapeutics — IPO & Funding Comparison

Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.

⚠️
Some data on this page may be outdated. We're verifying.
Data for Canva last verified: Aug 19, 2026. Data for Eikon Therapeutics last verified: Aug 20, 2026.
Metric Canva Eikon Therapeutics
Valuation$42B$5.2B
Total Funding$770M$1.27B
IPO StatusPrivatePrivate
SectorDesign & CreativeBiotechnology
StagePre-IPOSeries D
HeadquartersSydney, AustraliaHayward, CA
CEOMelanie PerkinsRoger Pomerantz
The IPO Stack Newsletter

Get Tuesday's IPO moves + one deep-dive in your inbox

Scores, valuations, and signals for Canva, Eikon Therapeutics, and 370+ companies. 5-min read every Tuesday.

Canva

Canva is the world's leading design platform with 250M+ users — valued at $48B with $770M raised. Track IPO timeline, funding rounds, and readiness score.

IndustryDesign & Creative
StagePre-IPO
IPO StatusPrivate
Valuation$42B
Total Funding$770M
HeadquartersSydney, Australia

Eikon Therapeutics

Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable targets.

IndustryBiotechnology
StageSeries D
IPO StatusPrivate
Valuation$5.2B
Total Funding$1.27B
HeadquartersHayward, CA

Get the Full Report on Any Company — One-Time $19

Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.

Get All 375+ Reports — $49/mo

Or buy any single company report for $19

Frequently Asked Questions

What is the Canva vs Eikon Therapeutics valuation in 2026? +

Canva is valued at $42B. Eikon Therapeutics is valued at $5.2B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.

How does Canva revenue compare to Eikon Therapeutics? +

Canva reported 4000000000 revenue in 2025. Eikon Therapeutics's revenue is not publicly disclosed. Revenue figures are sourced from TechStackIPO's company database and updated as new data becomes available.

Which is more likely to IPO first — Canva or Eikon Therapeutics? +

Canva filed an S-1 in November 2025 and is actively in the IPO pipeline. Eikon Therapeutics is currently private. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.

How much has each company raised in total funding? +

Canva has raised $770M. Eikon Therapeutics has raised $1.27B.

Are Canva and Eikon Therapeutics in the same sector? +

Canva operates in Design & Creative, while Eikon Therapeutics operates in Biotechnology.

What are the key differences between Canva and Eikon Therapeutics as investments? +

Canva is a Design & Creative company valued at $42B with $770M raised. Eikon Therapeutics is a Biotechnology company valued at $5.2B with $1.27B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.

How can I invest in Canva or Eikon Therapeutics before their IPO? +

Accredited investors can access pre-IPO shares in Canva and Eikon Therapeutics through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.

📡 IPO Intelligence
$49/mo — Unlimited Reports + Real-Time Updates
Unlimited company analysis reports — all 375+ companies
Real-time IPO alerts — know the moment S-1s are filed
Verified data updated daily — not chatbot hallucinations
💡 Tracking multiple companies? Full access pays for itself after 3 reports.
$49
per month
Subscribe Now →
Cancel anytime · Secure via Stripe
Institutional Research
$19 — Get the Complete canva vs eikon therapeutics Analysis Brief
Executive summary & IPO readiness breakdown
Competitive positioning & funding trajectory
Bull / bear thesis with pricing projections
S-1 timeline estimate & risk assessment
$19
One-time
Don't find it useful? Refund within 7 days.
Secure checkout · Stripe · 24h delivery